

Consolidated Financial Statements and Consolidating Information

June 30, 2016 and 2015

(With Independent Auditors' Report Thereon)

Table of Contents

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7–36
Consolidating Information:	
Consolidating Balance Sheet	37
Consolidating Statement of Operations	38
Consolidating Statement of Changes in Net Assets	39



KPMG LLP 1 East Pratt Street Baltimore, MD 21202-1128

Independent Auditors' Report

The Board of Directors GBMC HealthCare, Inc.:

We have audited the accompanying consolidated financial statements of GBMC HealthCare, Inc. and its subsidiaries (the Company), which comprise the consolidated balance sheets as of June 30, 2016 and 2015, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of GBMC HealthCare, Inc. and its subsidiaries as of June 30, 2016 and 2015, and the results of their operations and their cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.



Other Matter

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary information in Schedules 1–3 is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.



October 6, 2016

Consolidated Balance Sheets

June 30, 2016 and 2015

(In thousands)

Assets		2016	2015
Current assets: Cash and cash equivalents Short-term investments and limited or restricted use funds Patient accounts receivable, net of reserves of \$10,685 and \$11,041 Other receivables Other current assets	\$	46,632 12,195 54,429 11,977 11,560	40,188 18,565 56,195 14,252 9,229
Total current assets		136,793	138,429
Noncurrent assets: Investments and limited or restricted use funds Property, plant and equipment, net Other assets	_	360,886 279,604 34,412	381,092 260,060 28,818
Total noncurrent assets		674,902	669,970
Total assets	\$	811,695	808,399
Liabilities and Net Assets		_	
Current liabilities: Accounts payable and accrued expenses Insurance reserves, current Advances from third-party payors Current portion of long-term debt and capital lease liabilities Other current liabilities	\$	64,958 12,700 12,563 12,300 6,956	58,353 12,998 12,309 12,324 6,128
Total current liabilities		109,477	102,112
Noncurrent liabilities: Long-term debt Capital lease liabilities Insurance reserves Pension liability Other long-term liabilities		130,530 27,332 42,805 60,498 5,947	141,668 27,489 38,883 37,532 7,341
Total liabilities		376,589	355,025
Net assets: Unrestricted controlling interest Unrestricted noncontrolling interest	_	361,531 5,641	383,799 4,833
Total unrestricted		367,172	388,632
Temporarily restricted Permanently restricted		37,786 30,148	36,180 28,562
Total net assets	<u></u>	435,106	453,374
Total liabilities and net assets	\$	811,695	808,399

Consolidated Statements of Operations

Years ended June 30, 2016 and 2015

(In thousands)

	 2016	2015
Patient service revenue:		
Patient service revenue, net of contractual allowances	\$ 516,362	494,682
Provision for uncollectible accounts	 (13,599)	(13,230)
Net patient service revenue	502,763	481,452
Other operating revenue	18,201	20,115
Net assets released from restrictions	 10,211	11,438
Total operating revenue	 531,175	513,005
Operating expenses:		
Salaries, wages and employee benefits	319,719	305,386
Expendable supplies	89,335	85,621
Purchased services	79,533	75,913
Depreciation and amortization	30,738	31,529
Interest	 7,147	6,879
Total operating expenses	 526,472	505,328
Total operating income	 4,703	7,677
Other income:		
Contributions	1,284	1,248
Fund-raising expense	(3,911)	(3,230)
Investment (loss) income, net	(3,020)	5,739
Inherent contribution	 	1,357
Total other (loss) income	 (5,647)	5,114
(Deficit) excess of revenues over expenses	\$ (944)	12,791

Consolidated Statements of Changes in Net Assets

Years ended June 30, 2016 and 2015

(In thousands)

		2016	2015
(Deficit) excess of revenues over expenses Changes in unrestricted net assets:	\$	(944)	12,791
Pension-related changes other than net periodic pension costs		(20,458)	(16,149)
Net assets released for purchase of fixed assets		917	736
Distribution to noncontrolling interest		(975)	(1,691)
Decrease in unrestricted net assets	_	(21,460)	(4,313)
Changes in temporarily restricted net assets:			
Contributions		13,731	10,870
Investment (loss) income, net		(997)	784
Net assets released for operations		(10,211)	(11,438)
Net assets released for purchase of fixed assets		(917)	(736)
Inherent contribution			31
Increase (decrease) in temporarily restricted net assets		1,606	(489)
Changes in permanently restricted net assets:			
Contributions		1,697	2,201
Net unrealized loss on investments		(111)	(89)
Inherent contribution			2,322
Increase in permanently restricted net assets		1,586	4,434
Decrease in net assets		(18,268)	(368)
Net assets, beginning of year		453,374	453,742
Net assets, end of year	\$	435,106	453,374

Consolidated Statements of Cash Flows

Years ended June 30, 2016 and 2015

(In thousands)

	2016	2015
Cash flows from operating activities:		
	\$ (18,268)	(368)
Adjustments to reconcile decrease in net assets to net		
cash provided by operating activities:		
Depreciation and amortization	30,738	31,529
Provision for uncollectible accounts	13,599	13,230
Realized and unrealized loss (gains) on investments	9,541	(1,168)
Pension-related changes other than net periodic pension costs	20,458	16,149
Restricted investment income	(689)	(699)
Restricted contributions	(15,428)	(13,071)
Unrealized gains on joint ventures	(779)	(1,102)
Distribution to noncontrolling interest	975	1,691
Inherent contribution Changes in assets and liabilities:	_	(3,710)
Increase in patient accounts receivable	(11,833)	(15,111)
Increase in other receivables and other assets	(1,962)	(2,582)
Increase in accounts payable and accrued expenses,	(1,702)	(2,302)
advances from third parties, current and non current		
liabilities	1,559	5,167
Increase in pension liability	2,508	44
Net cash provided by operating activities	30,419	29,999
Cash flows from investing activities:		
Decrease (increase) in investments and limited or restricted use funds	18,503	(55,908)
Additions to property and equipment	(41,839)	(23,474)
Cash assumed in connection with Joseph Richey Hospice acquisition	· —	245
Net cash used in investing activities	(23,336)	(79,137)
Cash flows from financing activities:		
Payment on long-term debt and capital lease liabilities	(11,297)	(6,498)
Payments for financing costs	(11, 2 >7)	(325)
Proceeds from bond issuance	_	50,000
Proceeds from restricted contributions	11,633	13,175
Distributions to noncontrolling interest	(975)	(1,691)
Net cash (used in) provided by financing activities	(639)	54,661
Increase in cash	6,444	5,523
Cash and cash equivalents, beginning of year	40,188	34,665
Cash and cash equivalents, end of year	\$ 46,632	40,188
Cash paid during the year for interest	\$ 7,307	6,686
Capital additions accrued but not paid	8,358	8,383
capital additions accided out not paid	0,550	0,505

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(1) Organization and Consolidation

GBMC HealthCare, Inc. (the Company), is a holding company for nonprofit companies, which include: Greater Baltimore Medical Center, Inc. (Medical Center), Greater Baltimore Health Alliance, Physicians, LLC, GBMC Foundation, Inc., Gilchrist Hospice Care, Inc., GBMC Land, Inc., and GBMC Investments, Inc.

The Medical Center is a wholly owned not-for-profit hospital, which provides in-patient, outpatient, and emergency care services primarily for residents of the Baltimore metropolitan area. In addition, the Medical Center has ownership of Ruxton Insurance Company, Ltd., an insurance captive domiciled in Bermuda. Ruxton insures the risks for malpractice and general liability claims. The Medical Center was formed by agreement dated September 1, 1965, by the Hospital for Women of Maryland of Baltimore City (Women's Hospital) and Presbyterian Eye, Ear and Throat Charity Hospital (Presbyterian Hospital).

Greater Baltimore Health Alliance Physicians, LLC (GBHA), is a wholly owned not-for-profit accountable care organization, which integrates community primary care with hospital and multi-specialty care in the Baltimore area.

GBMC Foundation, Inc. (Foundation) is a wholly owned not-for-profit organization, which coordinates fundraising efforts to benefit the Company and its subsidiaries.

Gilchrist Hospice Care, Inc. d/b/a Gilchrist Services, Inc. (the Hospice) is a wholly owned not-for-profit organization, which provides inpatient and home hospice care in the greater Baltimore area. On October 31, 2014, Hospice entered into an affiliation agreement with Joseph Richey House, Inc. (JRH) and Brownlow Byron Home, Inc. (BBH), collectively referred to as Richey, under which the Hospice became the sole member of JRH and BBH. Richey was consolidated into the operations of the Hospice effective November 1, 2014. The Hospice recognized an inherent contribution equal to the estimated fair value of the identifiable net assets of Richey on the acquisition date of \$3,710, of which \$1,357 was included in nonoperating income on the consolidated statement of activities and \$31 and \$2,322 were included in temporarily restricted and permanently restricted inherent contributions, respectively, and reported in the consolidated statement of changes in net assets. Hospice assumed \$6,970 in assets and \$3,260 in liabilities in this transaction.

GBMC Land, Inc. (Land) is a wholly owned not-for-profit organization, which operates Physicians Pavilion North, a medical building on the campus of the Medical Center.

GBMC Investments, Inc. is a wholly owned not-for-profit organization, which holds investments of the Company and is the parent of the following for-profit subsidiaries:

GBMC Agency, Inc. (Agency), which has ownership interest in various medical services companies as follows:

- GBMC Physicians, LLC, a multi-specialty physician healthcare provider.
- Greater Baltimore Diagnostic Imaging Partners, LLC (GBDIP), a diagnostic imaging company, which is 50% owned and consolidated in the financial statements of the Company.

7

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

- GBMC Pavilion West Medical Arts Limited Partnership, a Maryland limited partnership, which owns
 and operates the five upper floors and has interest in certain common areas of Physicians Pavilion
 West, a medical office building on the campus of the Medical Center.
- GBMC Management, Inc., which owns and operates Physicians Pavilion East, a medical office building on the campus of the Medical Center.

(2) Summary of Significant Accounting Policies

(a) Basis of Accounting

The accompanying consolidated financial statements have been prepared on an accrual basis of accounting in accordance with U.S. generally accepted accounting principles.

(b) Consolidation of Subsidiaries

The Company's consolidated financial statements include the subsidiaries in which the Company has 50% or more voting interests or when the Company is deemed to have control. Significant intercompany accounts and transactions have been eliminated in consolidation.

(c) Cash and Cash Equivalents

Cash and cash equivalents, carried at cost which approximates fair value, include short-term investments with original maturities of three months or less from the date of purchase invested that are readily convertible to known amounts of cash. Cash balances may exceed amounts insured by federal agencies and, therefore, bear a risk of loss. The Company has not experienced such losses on these funds.

(d) Limited or Restricted Use Funds Held

Limited or restricted use funds primarily include assets held by trustees under agreement. Such funds include assets set aside for bond repayment, malpractice costs, capital replacement, and amounts restricted by donors. Independent third parties designate the assets held by trustees under agreement. The limited or restricted use funds are classified as current or noncurrent based upon the timing and nature of their intended use.

(e) Inventories

Inventories, consisting of medical supplies and drugs are stated at the lower of cost or market, with cost being determined primarily under the first-in, first-out method.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(f) Investments and Investment Income

Investments include amounts designated by management for specific purposes, insurance reserves, plant replacement, and other purposes. The Company's investment portfolio is considered a trading portfolio, with the exception of the alternative investments, and is classified as current or noncurrent assets based on management's intention as to use. Limited or restricted use funds that are required for obligations classified as current liabilities are reported as current assets. Investments in marketable securities are measured at fair market value on the consolidated balance sheets. The fair value of the investments, with the exception of the alternative investments, is based on quoted market prices or dealer quotations. See note 4 for discussion of the measurement of fair value for investments.

Alternative investments are recorded under the equity method of accounting. Underlying securities of these alternative investments may include certain debt and equity securities that are not readily marketable. Because certain investments are not readily marketable, their fair value is subject to additional uncertainty, and therefore, values realized upon disposition may vary significantly from current reported values.

Investment income or loss (including realized gains and losses on investments, interest and dividends) on proceeds of borrowings that are held by a trustee, to the extent not capitalized, and investment income on assets deposited in the insurance captive investment is reported as other operating income. Investment income or loss (including unrealized and realized gains and losses on investments, interest and dividends) from all other unrestricted fund investments is included in (deficit) excess of revenues over expenses unless restricted by donor or law. Investment income on investments of temporarily restricted net assets is recorded as an increase in temporarily restricted net assets to the extent restricted by the donor or law.

Investment income is recorded on the accrual basis. Purchases and sales of investments are reflected on a trade-date basis. Realized gains and losses on sales of investments are based on historical cost.

(g) Property, Plant and Equipment

Property, plant and equipment are recorded at cost or, if donated, at fair market value at date of gift. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 2 to 40 years. The cost and accumulated depreciation relating to property, plant and equipment sold or retired are removed from the respective accounts at the time of disposition and the resulting gain or loss is reflected in other operating income in the consolidated statements of operations.

Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted support, and are excluded from the (deficit) excess of revenues over expenses, unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(h) Other Noncurrent Assets

Other assets comprise the following items:

	 2016	2015
Reinsurance receivable	\$ 14,877	12,634
Goodwill	7,593	7,593
Pledges receivable	8,912	5,175
Deferred costs	2,405	2,609
Equity investments	267	274
Other	 358	533
	\$ 34,412	28,818

Goodwill is assessed annually for impairment at the reporting unit. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment tests as described in Accounting Standards Codification, Topic 350, *Intangibles – Goodwill and Other*. The more likely than not threshold is defined as having a likelihood of more than 50%.

In fiscal year 2012, the Company acquired an additional interest in Magnetic Imaging of Baltimore, LLC (MIB), which resulted in the Company having to consolidate MIB. The Company recorded this acquisition using the purchase accounting method and recorded goodwill of \$7,593. At June 30, 2016 and 2015, the Company assessed the goodwill for its reporting unit, GBDIP, for impairment. The Company determined that it was not more likely than not that the fair value of GBDIP was less than its carrying amount. Accordingly, the Company concluded that goodwill was not impaired as of June 30, 2016 and 2015 without having to perform the two-step impairment test.

Deferred costs, include deferred financing costs related to long-term borrowings, are amortized on a straight-line basis, which approximates the effective interest rate method, over the life of the borrowings, which ranges from 2 to 30 years. The Company has incurred deferred financing costs related to the issuance of Maryland Health and Higher Educational Facilities Authority (MHHEFA) Series 2012, Series 2011, Series 1995 Revenue Bonds and 2015 PNC Bank term note payable that have been capitalized.

Deferred costs also include deferred leasing costs and prepaid land lease payments, which are amortized over the lease terms and expensed on a straight-line basis over the life of the related lease.

Amortization expense for deferred leasing, prepaid land lease, and bond financing costs for the years ended June 30, 2016 and 2015 was \$253 and \$233, respectively. Accumulated amortization at June 30, 2016 and 2015 amounted to \$1,126 and \$918, respectively.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

The Company accounts for its joint ventures using the equity method or at cost, as appropriate, and any income (loss) is included in other operating revenues in the consolidated statements of operations.

(i) Donor-Restricted Gifts

Unconditional promises to give cash and other assets to the Company are reported at their fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received. The gifts are reported as either temporarily or permanently restricted if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose of the restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and reported in the consolidated statements of operations and changes in net assets as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying consolidated financial statements.

(j) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets are those whose use by the Company has been limited by donors to a specific time period or purpose. Permanently restricted net assets have been restricted by donors to be maintained by the Company in perpetuity.

Richey is one of six named beneficiaries of a charitable trust and receives annual distributions for 50 years, which began in 2005. The distributions are to be used for the unrestricted general charitable purpose of the Richey. After the 50 years, the trust corpus will be distributed to the charities as long as they continue to qualify as a charitable organization under Sections 171(c) and 2055(a) of the Internal Revenue Code. The corpus must be used to create an endowment fund that is permanently restricted, and the income should be used for the organization's unrestricted general charitable purpose. The fair value of the trust is included in permanently restricted net assets.

(k) Insurance Reserves

The provision for estimated insurance reserves include estimates of the ultimate costs for reported malpractice, health and workers' compensation claims and claims incurred but not reported.

(1) Net Patient Service Revenue

Net patient service revenue is reported at the estimated net realizable amounts from patients and third-party payors for services rendered. Rates for the Medical Center's facility-based patient service charges are established in accordance with the regulations and rate methodologies of Maryland's rate-setting authority, the Health Services Cost Review Commission (HSCRC), an independent agency of the Maryland State government. With the exception of relatively small contractual allowances, the HSCRC allows a discount of 6.0% to Medicare and Medicaid as well as a 2.25% prompt pay discount for other participating payors, HSCRC regulations stipulate that all payors must reimburse the Medical Center on the basis of the charges approved by the HSCRC and billed by the Medical Center.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

During the years ended June 30, 2016 and 2015, the Medical Center participated in the HSCRC Global Budget Revenue (GBR) methodology, which provides a revenue target and maximum amount of facility-based revenue for the Medical Center during a fiscal year, and is not intended to fluctuate during the fiscal year with respect to changes in volume. The GBR model is consistent with the Medical Center's mission of controlling utilization of acute-care services by managing a patient's total spectrum of medical care. The GBR agreement allows the Medical Center to adjust unit rates, within certain limits, to achieve the overall revenue base for the Medical Center at year-end. Any overcharge or undercharge versus the GBR cap is prospectively added to the subsequent year's GBR cap. While the GBR cap does not adjust for changes in volume or service mix, the GBR cap is adjusted annually for inflation, and for changes in payor mix, market share and uncompensated care. The HSCRC also may impose various other revenue adjustments that could be significant in the future.

Physician charges are not regulated by the HSCRC, and are primarily reimbursed by third-party payors at rates that are contractually agreed upon.

Hospice's net revenue is reported at the estimated net realizable amounts from third-party payors who pay on a per-diem basis.

Adjustments to patient service revenue for HSCRC related assessments, contractual allowances, discounts, and financial assistance were \$152,573 and \$132,359 for the years ended June 30, 2016 and 2015, respectively.

(m) Allowance for Bad Debts

Patient accounts receivable are reduced by allowances for bad debts. In evaluating the collectibility of accounts receivable, the Company analyzes historical collections and write-offs and identifies trends for each of its major payor sources of revenue to estimate the appropriate allowance for bad debts and provision for uncollectible accounts. Management regularly reviews its estimate and evaluates the sufficiency of the allowance for bad debts. The Company analyzes contractual amounts due from patients who have third-party coverage and provides an allowance for doubtful accounts and a provision for bad debts. For patient accounts receivable associated with self-pay patients, which includes those patients without existing insurance coverage for a portion of the bill, the Company records a significant provision for bad debts for patients that are unable or unwilling to pay for the portion of the bill representing their financial responsibility. Account balances are charged off against the allowance for doubtful accounts after all means of collection have been exhausted.

The Company's allowance for doubtful accounts remained the same at 14% of gross accounts receivable as of June 30, 2016 and June 30, 2015.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

The activity in the allowance for bad debts is summarized as follows for the years ended June 30:

	 2016	2015
Beginning balance	\$ 11,041	9,160
Provision for uncollectible accounts	13,599	13,230
Less write-offs	 (13,955)	(11,349)
Ending balance	\$ 10,685	11,041

(n) Meaningful Use of Electronic Health Records

Under certain provisions of the American Recovery and Reinvestment Act of 2009 (ARRA), federal incentive payments are available to hospitals, physicians and certain other professionals (Providers) when they adopt, implement or upgrade (AIU) certified electronic health record (EHR) technology or become "meaningful users," as defined under ARRA, of EHR technology in ways that demonstrate improved quality, safety and effectiveness of care. Providers can become eligible for annual Medicare incentive payments by demonstrating meaningful use of EHR technology in each period over four periods. Medicaid providers can receive their initial incentive payment by satisfying AIU criteria, but must demonstrate meaningful use of EHR technology in subsequent years in order to qualify for additional payments. Hospitals may be eligible for both Medicare and Medicaid EHR incentive payments; however, physicians and other professionals may be eligible for either Medicare or Medicaid incentive payments, but not both. The Company recognizes Medicare EHR incentive payments when it is reasonably assured that the Company will successfully demonstrate compliance with the specified meaningful use criteria. The Medical Center and certain physicians satisfied the Centers for Medicare & Medicaid Services (CMS) AIU and/or meaningful use criteria. As a result, the Company recognized approximately \$359 and \$1,410 of Medicare and Medicaid EHR incentive payments in other operating revenues in the consolidated statements of operations for the years ended June 30, 2016 and 2015, respectively.

(o) (Deficit)Excess of Revenue over Expenses

The consolidated statements of operations include a performance indicator, (deficit) excess of revenues over expenses. Changes in unrestricted net assets that are excluded from (deficit) excess of revenues over expenses, consistent with industry practice include pension changes other than net periodic pension costs, contributions and distributions with noncontrolling investors, and contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for the purpose of acquiring such assets).

(p) Financial Assistance and Community Benefits

As part of the Company's mission, it provides medical care without discrimination, including the ability of a patient to pay for services. Under the Company's Financial Assistance Policy, patients who meet certain financial based criteria can qualify for free care on all or a portion of the total patient bill. The Company recorded \$2,367 and \$1,786 of financial assistance during the years ended June 30,

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

2016 and 2015, respectively. The total direct and indirect cost of providing financial assistance was approximately \$1,728 and \$1,349 during the fiscal years ended June 30, 2016 and 2015, respectively.

In addition to its Financial Assistance Policy, the Company has a long-standing commitment of supporting the community through the provision of outreach services designed to address identified health and social issues. Specifically, the Company provides a variety of screening and early detection tests, wellness activities, social support services and educational seminars. A majority of these services are provided at either nominal or no cost to community members.

(q) Rental Income

Base rental income is recognized as revenue on a straight-line basis over the life of the lease. The difference between the rent recognized and the rental income as stipulated in the lease agreement has been recognized as a receivable in the accompanying consolidated balance sheets from inception of the lease. Rental income is included in other operating income in the accompanying consolidated statements of operations.

(r) Income Taxes

Income taxes are provided for earnings (loss) of those subsidiaries which are subject to federal and state income tax based on the Company's share of the subsidiaries' taxable income, whether or not distributed. The Company's share of these subsidiaries' net losses is deductible to the extent of the Company's tax basis in the subsidiaries.

The Financial Accounting Standards Board's (FASB) guidance on accounting for uncertainty in income taxes clarifies the accounting for uncertainty of income tax positions. This guidance defines the threshold for recognizing tax return positions in the consolidated financial statements as "more likely than not" that the position is sustainable, based on its technical merits. This standard also provides guidance on the measurement, classification and disclosure of tax return positions in the consolidated financial statements. The Company has adopted this guidance, and there were no amounts recorded in the consolidated financial statements as of and during the years ended June 30, 2016 and 2015 for uncertain tax positions.

The subsidiaries of GBMC Investments, Inc. are taxable entities. An operating loss carry forward of approximately \$109,881 is available to offset future taxable income through the year 2035. As of June 30, 2016 and 2015, deferred tax assets of \$46,828 and \$39,422, respectively, consisting primarily of net operating loss carry forwards, were offset by a related valuation allowance.

(s) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(t) New Accounting Pronouncements

The FASB issued Accounting Standards update (ASU) 2014-09, *Revenue from Contracts with Customers (Topic 606)*. This ASU establishes principles for reporting useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from the entity's contracts with customers. Particularly, that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for fiscal year 2019. The Company expects to record a decrease in net patient service revenue related to self-pay patients and a corresponding decrease in bad debt expense upon the adoption of the standard.

The FASB issued ASU 2015-03, *Interest – Imputation of Interest*. This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. This ASU requires retrospective application to all prior periods presented in the financial statements. ASU 2015-03 is effective for fiscal year 2017. The Company does not anticipate that the adoption of this ASU will have a material impact on its financial position or its results of operations.

The FASB issued ASU No. 2016-02, *Leases (ASU 2016-02)*, which will require lessees to recognize most leases on-balance sheet, which will increase their reported assets and liabilities. The adoption of ASU 2016-02 is effective in fiscal year 2020, and will require application of the new guidance at the beginning of the earliest comparable period presented. Early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU No. 2016-02, which is expected to increase the Company's assets and liabilities but not have a significant impact on the results of operations.

The FASB issued ASU No. 2016-14, *Not-for-Profit Entities* (ASU 2016-14), which amends the requirements for financial statements and notes in Topic 958, Not-for-Profit Entities (NFP), and requires a NFP to:

- Reduce the number of net asset classes presented from three to two, with donor restrictions and without donor restrictions;
- Require all NFPs to present expenses by their functional and their natural classifications in one location in the financial statements;
- Require NFPs to provide quantitative and qualitative information about management of liquid resources and availability of financial assets to meet cash needs within one year of the balance sheet date;

The adoption of ASU 2016-14 is effective in fiscal year 2019, and is applied retrospectively in the year of adoption. The Company does not anticipate that the adoption of this ASU will have a material impact on its financial position and results of operations.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

The FASB issued ASU 2015-07, Fair Value Measurement (Topic 820) Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share. This ASU removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The amendments also remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. ASU 2015-07 is effective in fiscal year 2017. This ASU requires retrospective application to all prior periods presented. The Company does not anticipate that the adoption of this ASU will have a material impact on its financial position or its results of operations.

(3) Concentration of Credit Risk

The Company grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables and patient service revenue from patients and third parties as of June 30, 2016 and 2015 was as follows:

	Accounts receivable		Revenue	
	2016	2015	2016	2015
Medicare	34%	33%	42%	40%
Medicaid	5	5	3	3
Blue cross	13	14	17	17
HMO	22	22	21	21
Other third-party payors	20	20	16	18
Self-pay	6	6	1	1
Total	100%	100%	100%	100%

The Company provides general acute healthcare services in the State of Maryland. The Company and other healthcare providers are subject to certain inherent risks, including the following:

- Dependence on revenues derived from reimbursement by the federal Medicare and state Medicaid programs
- Regulation of hospital rates by the State of Maryland Health Services Cost Review Commission
- Government regulation, government budgetary constraints and proposed legislative and regulatory changes, and
- Lawsuits alleging malpractice or other claims

Such inherent risks require the use of certain management estimates in the preparation of the Company's consolidated financial statements and it is reasonably possible that a change in such estimates may occur.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

The Medicare and state Medicaid reimbursement programs represent a substantial portion of the Company's revenues and the Company's operations are subject to a variety of other federal, state and local regulatory requirements. Failure to maintain required regulatory approvals and licenses and/or changes in such regulatory requirements could have a significant adverse effect on the Company.

Changes in federal and state reimbursement funding mechanisms and related government budgetary constraints could have a significant adverse effect on the Company.

The federal government and many states have aggressively increased enforcement under Medicare and Medicaid anti-fraud and abuse laws and physician self referral laws (STARK law and regulation). Federal healthcare reform initiatives continue to prompt a national review of federally funded healthcare programs. In addition, the federal government and many states continue to fund programs to audit and recover potential overpayments to providers from the Medicare and Medicaid programs. The Company began receiving Recovery Audit Contractors (RAC) and Additional Development Request (ADR) in 2011 and 2009, respectively. The Company has devoted resources to track and defend RAC and ADR requests and implemented a response program and compliance program to monitor conformance with applicable laws and regulations, but the possibility of future government review and enforcement action exists.

As a result of recently enacted and pending federal healthcare reform legislation, substantial changes are anticipated in the United States healthcare system. Such legislation includes numerous provisions affecting the delivery of healthcare services, the financing of healthcare costs, reimbursement to healthcare providers and the legal obligations of health insurers, providers and employers. These provisions are currently slated to take effect at specified times over the next decade. This federal healthcare reform legislation did not affect the 2016 or 2015 consolidated financial statements.

(4) Investments and Limited or Restricted Use Funds

Guidance for fair value measurements establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the reporting entity and unobservable inputs reflect the entities own assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value under current guidance must maximize the use of observable inputs and minimize the use of unobservable inputs. The guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last one is considered unobservable, that may be used to measure fair value.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the Company for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities.
- Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities.

• Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The tables below present the balances of assets measured at fair value by levels excluding alternative investments in the amount of \$2,684 and \$2,356, which are accounted for under the equity method, as of June 30 2016 and 2015, respectively:

			June 30), 2016	
Assets		Level 1	Level 2	Level 3	Total
Managed cash funds	\$	20,170	_	_	20,170
Corporate debt securities		15 796	40,365	_	40,365
Bonds – treasury Bonds – federal-agency-backed		15,786	8,992	_	15,786 8,992
Bonds – mortgage-backed		_	1,545	_	1,545
Bonds – fixed income		_	1,125	_	1,125
Mutual funds – fixed income		_	90,507	_	90,507
Municipal bonds	_		918		918
Total fixed income		15,786	143,452		159,238
Common stock Foreign stock Mutual funds Mutual funds international		133,390 9,590 43,231 520	3,395 — — —	863 	137,648 9,590 43,231 520
Total equity		186,731	3,395	863	190,989
Total investment and limited or restricted use funds		222,687	146,847	863	370,397
			,		
Current portion	_	12,195			12,195
Total noncurrent investment and limited or restricted use funds	\$	210,492	146,847	863	358,202

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

June 30, 2015

	June 30, 2015				
Assets		Level 1	Level 2	Level 3	Total
Managed cash funds	\$	36,261	_	_	36,261
Corporate debt securities		_	64,132	_	64,132
Bonds – treasury		10,042		_	10,042
Bonds – federal-agency-backed		_	5,787	_	5,787
Bonds – mortgage-backed		_	1,583	_	1,583
Bonds – fixed income		_	464	_	464
Mutual funds – fixed income		_	88,495	_	88,495
Municipal bonds	_		1,144		1,144
Total fixed income	_	10,042	161,605		171,647
Common stock		128,373	2,332	1,070	131,775
Foreign stock		11,759	_		11,759
Mutual funds		45,236	_	_	45,236
Mutual funds international	_	623			623
Total equity	_	185,991	2,332	1,070	189,393
Total investment and limited or restricted					
use funds		232,294	163,937	1,070	397,301
Current portion	_	18,565			18,565
Total noncurrent investment and limited or restricted use funds	\$	213,729	163,937	1,070	378,736
doc funds	Ψ=	213,127	103,737	1,070	370,730

As of June 30, 2016, the alternative investments consisted of subscription partnership agreements with capital commitments of approximately \$14 million which are subject to periodic distributions. These alternative investments are valued at fair value using NAV or equivalent as determined by the General Partner in the absence of readily ascertainable market values. Distributions under this investment structure are made to investors through the liquidation of the underlying assets. All assets are unable to be fully distributed to the limited partners until the dissolution of the partnership, which may not be until a point in the future. The fair value of limited partnership interests is generally based on fair value capital balances reported by the underlying partnerships, subject to management review and adjustment. Security values of companies traded on exchanges, or quoted on NASDAQ, are based upon the last reported sales price on the valuation date. Security values of companies traded over the counter, but not quoted on NASDAQ, and securities for which no sale occurred on the valuation date are based upon the last quoted bid price. The value of any security for which a market quotation is not readily available may be its cost, provided however, that the General Partner adjusts such cost value to reflect any bona fide third party transactions in such a security between knowledgeable investors, of which the General Partner has knowledge. In the absence of

19

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

any such third party transactions, the General Partner may use other information to develop a good faith determination of value. Examples include, but are not limited to, discounted cash flow models, absolute value models, and price multiple models. Inputs for these models may include, but are not limited to, financial statement information, discount rates, and salvage value assumptions.

As of June 30, 2016 and 2015, the Level 3 investments consist of holdings of donated stock in a closely held company of \$863 and \$1,070, respectively. The value of the donated stock is based on independent appraisals obtained by the closely held company. There were no significant transfers between levels during the years ended June 30, 2016 and 2015.

Investments and limited or restricted use funds comprise the following uses and purposes at June 30:

		2016	2015
Funds for debt service	\$	5,787	5,638
Insurance settlements		55,505	51,881
Donor-restricted		54,051	54,653
Unrestricted	_	257,738	287,485
	\$	373,081	399,657

Investment income and gains for cash and cash equivalents and investments and limited use funds comprise the following for the years ended June 30:

	 2016	2015
Unrestricted income (loss): Dividends and interest, net	\$ 4.724	1567
Realized gains on sales of investments Unrealized loss on investments	 4,724 5,010 (12,754)	4,567 14,641 (13,469)
Total unrestricted (loss) income	 (3,020)	5,739
Temporarily restricted income (loss): Dividends and interest, net Realized gains on sales of investments Unrealized loss on investments	 689 1,008 (2,694)	699 1,247 (1,162)
Total temporarily restricted (loss) income	 (997)	784
Permanently restricted income (loss): Unrealized loss on investments	 (111)	(89)
	 (111)	(89)
Total investment (loss) income, net	\$ (4,128)	6,434

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(5) Property, Plant and Equipment

The following is a summary of the cost of property, plant and equipment as of June 30:

		2016	2015
Land and land improvements	\$	23,273	23,365
Buildings and building service equipment		375,624	372,966
Movable equipment		223,361	215,152
Capital leases		40,605	41,153
Construction in progress	_	46,074	14,974
		708,937	667,610
Less accumulated depreciation and amortization		(429,333)	(407,550)
Total property, plant and equipment, net	\$	279,604	260,060
Depreciation expense	\$	30,287	31,203
Amortization expense		451	326
Total depreciation and amortization expense	\$	30,738	31,529

The construction in progress balance includes \$30 million of costs related to the Company's electronic medical record system, which became operational in October 2016.

(6) Long-Term Debt

Long-term debt as of June 30 consisted of the following:

	 2016	2015
MHHEFA project and refunding revenue bonds:		
2015 PNC Bank term note – 2.3%	\$ 41,665	48,346
Series 2012 bonds:		
3.25%–5.00% term bonds	35,680	35,680
Series 2011 bonds:		
2.50%–5.75% term bonds	58,190	61,095
Series 1995 bonds:		
Variable rate serial bonds	4,945	5,335
M&T mortgage note – 5.5%	_	830
Note Payable 3.5%–4.5%	_	63
M&T line of credit 4.0%	_	436
Unamortized bond premium (discount)	 388	411
	140,868	152,196
Less current portion of long-term debt	 (10,338)	(10,528)
	\$ 130,530	141,668

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

On March 1, 2015, the Company obtained a \$50,000 taxable term note from PNC Bank, National Association to finance components of the system-wide integrated health record conversion and other capital projects. The 2015 note is due in monthly installments of \$647, and expires on March 1, 2022.

On April 11, 2012, MHHEFA issued \$35,680 of tax-exempt Revenue Bonds, Series 2012, on behalf of the Company. The bond proceeds and limited use funds were used to refund Series 2001 Revenue Bonds (\$40,265). The Series 2012 Bonds are due on July 1 in annual installments ranging from \$1,710 in 2022 to \$3,700 in 2034.

On April 20, 2011, MHHEFA issued \$67,945 of tax-exempt Revenue Bonds, Series 2011, on behalf of the Company. The bond proceeds and limited use funds were used to finance construction and renovation to the hospital and to refund, a) the Series 2009 Revenue Bonds (\$45,000); b) a portion of Series 2001 Revenue Bonds (\$12,565); and c) the Series 1993 Revenue Bonds (\$11,975). The Series 2011 bonds are due on July 1 in annual installments ranging from \$3,090 in 2016 to \$3,905 in 2034.

On October 4, 1995, MHHEFA issued \$10,000 of tax-exempt Revenue Bonds, Series 1995, on behalf of the Company. The Series 1995 bonds are due on July 1 in annual installments ranging from \$405 in 2016 to \$590 in 2025. The bonds bear interest at a variable rate, which is determined on a weekly basis by the remarketing agent of the issue. The rate was 0.72% and 0.28% as of June 30, 2016 and 2015, respectively.

The Series 1995 Bonds are supported by a Standby Bond Purchase Agreement issued by M&T Bank, covering the remaining portion of the obligation, effective through October 1, 2017.

The PNC 2015 note, Series 2012, 2011, and 1995 Revenue Bonds are collateralized equally and ratably by a lien on all gross receipts of the Company. The term note and bond proceeds were loaned to the Company pursuant to the Master Trust Indenture.

The aggregate future maturities of long-term debt as of June 30, 2016 are as follows:

	_	Long-Term Debt
2017	\$	10,338
2018		10,629
2019		10,964
2020		11,306
2021		11,666
Thereafter	_	85,577
		140,480
Unamortized bond premium	_	388
	\$ _	140,868

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

The fair value of the Company's long-term debt, which is estimated, based on quotes from underwriters, was approximately \$153,550 and \$159,341 as of June 30, 2016 and 2015.

Under the Master Trust Indenture, the Company is required to maintain, among other covenants, a maximum annual debt service coverage ratio of not less than 1.1 to 1.0.

In 2016, the Company did not renew a \$10,000 line of credit, which had expired on November 30, 2015 beared interest at the LIBOR Daily Floating Rate. No amounts were drawn on this line during the years ended June 30, 2016 or 2015.

(7) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets are available for the following purposes as of June 30:

		Available balance		Available balance Rel		Relea	eleased	
		2016	2015	2016	2015			
Departmental needs	\$	16,583	19,878	7,729	6,863			
Education		5,882	6,150	366	650			
Uncompensated care		2,890	4,421	1,027	1,229			
Research		2,566	3,060	836	562			
Time restriction	_	1,169	1,542	253	2,134			
Total temporarily								
restricted net assets		29,090	35,051	10,211	11,438			
Purchase of equipment/construction	_	8,696	1,129	917	736			
	\$	37,786	36,180	11,128	12,174			

Permanently restricted net assets at June 30 are restricted to investment in perpetuity, the income from which is expendable to support:

	 2016	2015
Departmental needs	\$ 13,850	12,272
Uncompensated care	10,182	10,182
Education	2,881	2,873
Research	2,725	2,725
General support	510	510
Total permanently restricted net assets	\$ 30,148	28,562

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

The Company's endowment fund consists of a \$14 million endowment for Hospice as well as other donations from individual donors. The Company has no internal board-designated endowment funds recorded in unrestricted net assets. The net assets associated with the endowment are classified and reported based on the existence or absence of donor-imposed restrictions.

The Company has interpreted the "Uniform Prudent Management of Institutional Funds Act" (UPMIFA) as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Company classifies as permanently restricted net assets the original value of the gifts donated to the permanent endowment. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the Company in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance, with UPMIFA, the Company considers the following factors in making a determination to appropriate or accumulate endowment funds:

- The duration and preservation of the fund
- The purposes of the Company and the donor-restricted endowment fund
- General economic conditions
- The possible effect of inflation and deflation
- The expected total return from income and the appreciation of investments
- Other resources of the organization
- The investment policies of the organization

Notes to Consolidated Financial Statements June 30, 2016 and 2015 (In thousands)

The Company had the following activities among its endowment fund during the years ended June 30 delineated by net asset class:

	_	Unrestricted	Temporary restricted	Permanently restricted	Total
Endowment net assets, June 30, 2014 Investment return:	\$	1,907	17,620	24,128	43,655
Investment income, net Net appreciation (depreciation)		45	789	_	834
(realized and unrealized)		19	375	(89)	305
Total investment return		64	1,164	(89)	1,139
Joseph Richey Acquisition Contributions Appropriation of endowment assets		_ _	_ _	2,322 2,201	2,322 2,201
for expenditure		(178)	(2,444)		(2,622)
Endowment net assets, June 30, 2015	-	1,793	16,340	28,562	46,695
Investment return (loss): Investment income, net Net depreciation (realized and		42	758	_	800
unrealized)	-	(76)	(1,501)	(111)	(1,688)
Total investment return (loss)		(34)	(743)	(111)	(888)
Contributions		_	_	1,697	1,697
Appropriation of endowment assets for expenditure	-	(161)	(2,331)		(2,492)
Endowment net assets, June 30, 2016	\$	1,598	13,266	30,148	45,012

(a) Endowment Funds with Deficits

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (deficit). When donor endowment deficits exist, they are classified as a reduction of unrestricted net assets. As of June 30, 2016, there were four endowments with deficits which were insignificant. There were no such deficits as of June 30, 2015.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(b) Return Objectives and Risk Parameters

The Company has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to maximize the return against a blended index, based on the endowment's target allocation applied to the appropriate individual benchmarks. The Company expects its endowment funds over time, to provide an average rate of return of approximately 7.5% annually. Actual returns in any given year may vary from this amount.

(c) Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, the Company relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yields (interest and dividends). The Company targets a diversified asset allocation that places greater emphasis on equity-based investments to achieve its long-term objectives within prudent risk constraints.

(d) Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives

The Board of Directors of the Company approves the method to be used to appropriate endowment funds for expenditure. The Company amended its endowment spending allocation policy to conform to UPMIFA, which was passed by Maryland on April 14, 2009 and limits annual endowment spending to 7% of the annual market value per year.

(8) Functional Expenses

The Company provides general healthcare services to residents within its geographic location. Expenses related to providing these services for the years ended June 30 were as follows:

	 2016	2015
Health care services	\$ 460,332	439,197
General and administrative	 66,140	66,131
Total operating expenses	\$ 526,472	505,328

(9) Leases

(a) Capital Leases

The Company is obligated under a long-term lease expiring in 2030 for the use of a medical office building. Payments increase at varying rates from \$2,483 and \$3,004 per year over the remaining life. Interest rates approximated 5.76% as of June 30, 2016 and 2015, respectively.

The Company leases medical equipment with annual payments ranging from \$243 to \$1,032 and the last lease expires in fiscal year 2020.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

Scheduled principal and interest payments on capital lease and financing obligations are as follows:

	_	Payment	Principal
2017	\$	3,517	1,962
2018		3,512	2,048
2019		3,353	1,981
2020		3,094	1,817
2021		2,975	1,790
Thereafter		25,266	19,696
		41,717	29,294
Less amount representing interest		(12,423)	
	\$	29,294	29,294

(b) Operating Leases

The Company leases land, office space, and equipment under leases ranging from 2 to 13 years. Options to renew these leases range from 1 to 10 years.

Minimum future rental expense for the years subsequent to June 30 is as follows:

	 Equipment	Facility	Total
2017	\$ 639	1,910	2,549
2018	639	1,666	2,305
2019	639	1,030	1,669
2020	639	700	1,339
2021	639	269	908
Thereafter	 	230	230
Total	\$ 3,195	5,805	9,000

Most of the Company's leases contain renewal options and provisions for pass-through of operating expenses and real estate taxes. These provisions are not included in the minimum future rental expense unless exercised. Rental expense, including pass-through, associated with the facility leases amounted to \$2,484 and \$2,042 for the years ended June 30, 2016 and 2015, respectively.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(10) Retirement Plans

(a) Defined Benefit Plan

The Company has two noncontributory defined benefit pension plans, Greater Baltimore Medical Center Retirement Plan (DB Non Union) and the Pension Plan for Members of the Bargaining Unit of Greater Baltimore Medical Center (DB Union), covering all full-time employees with at least one year of service. Benefits under the plans are determined based on increasing percentages (depending on years of service) of final average compensation. Annual contributions are made to these plans in accordance with the Employment Retirement Income Security Act (ERISA) regulations.

Effective June 30, 2007, the DB Non Union plan was frozen. As a result, no future benefits may be earned; however, employees are eligible to vest under the terms of the plan.

The following tables set forth the plans' funded status and amounts recognized in the Company's consolidated financial statements as of June 30, 2016 and 2015. The change in benefit obligation, plan assets, and funded status of the pension plans is as follows:

	 2016	2015
Change in benefit obligation:		
Benefit obligation at beginning of year	\$ 206,789	191,721
Service cost	971	921
Interest cost	9,170	8,336
Actuarial loss	17,891	12,428
Benefits paid	 (7,757)	(6,617)
Benefit obligation at end of year	 227,064	206,789
Change in plan assets:		
Fair value of plan assets at beginning of year	169,257	170,382
Actual return on plan assets	5,066	5,492
Employer contribution		_
Benefits paid	 (7,757)	(6,617)
Fair value of plan assets at end of year	\$ 166,566	169,257
Funded status at end of year	\$ (60,498)	(37,532)

Amounts recognized in unrestricted net assets as of June 30, 2016 and 2015 are as follows:

	_	2016	2015
Net prior service cost Net actuarial loss	\$	(1,107) 84,470	(1,479) 64,384
	\$	83,363	62,905

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

Components of net periodic benefit cost for the years ended June 30, 2016 and 2015 are as follows:

	 2016	2015
Service cost	\$ 971	921
Interest cost	9,170	8,336
Expected return on plan assets	(12,347)	(12,452)
Amortization of prior service cost	(372)	(372)
Amortization of loss deferral	 5,088	3,612
Net periodic pension benefit cost	\$ 2,510	45

Amounts in unrestricted net assets expected to be recognized as a component of net periodic pension benefit cost in fiscal year 2017:

Prior service cost	\$	(372)
Net actuarial loss	_	7,957
	\$	7,585

i) Assumptions

The weighted average assumptions used in developing the projected pension benefit obligations for the plans as of June 30, were as follows:

	Unio	n	Non union		
	2016	2015	2016	2015	
Discount rate Rate of compensation	3.87%	4.61%	3.87%	4.61%	
increase	4.00	4.00	_		

The weighted average assumptions used to determine the net periodic benefit costs for the plans as of June 30, were as follows:

	Unio	n	Non union		
Discount rate	2016	2015	2016	2015	
Discount rate Expected return on plan	4.61%	4.45%	4.61%	4.45%	
assets Rate of compensation	7.50	7.50	7.50	7.50	
increase	4.00	4.00			

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

The accumulated benefit obligation for the pension plans, which differs from the estimated actuarial present value of the projected benefit obligation because it is based on current rather than future compensation levels, was \$224,183 and \$204,532 as of June 30, 2016 and 2015, respectively. In 2015, GBMC adopted the new RP-2014 Mortality Table with generational improvements using projection scale MP-2014.

ii) Expected Long-Term Rate of Return

The expected long-term rate of return assumption used was based on a total plan return estimation by looking at the current yields available from fixed-income and reasonable equity return assumption based on long-term market trends and applying this to the plan's asset mix. In addition, the actual long-term historical returns realized by the pension plans were taken into consideration.

iii) Estimated Future Benefit Payments

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	 Non union	Union	Total
2017	\$ 8,387	1,363	9,750
2018	8,716	1,388	10,104
2019	8,990	1,489	10,479
2020	9,281	1,495	10,776
2021	9,665	1,529	11,194
2022 - 2026	 51,745	8,471	60,216
Total	\$ 96,784	15,735	112,519

The Company's pension plan weighted average asset allocations as of June 30 by asset category were as follows:

	2016	2015
Equity securities	34%	36%
Debt securities	64	62
Cash and cash equivalents	2	2
	100%	100%

Notes to Consolidated Financial Statements June 30, 2016 and 2015 (In thousands)

The following tables set forth by level, within the fair value hierarchy, the Plan's assets at fair value as of June 30:

		June 30, 2016					
		Level 1	Level 2	Level 3	Total		
Managed cash funds	\$	2,798	_	_	2,798		
Mutual funds – fixed income		· —	50,638	_	50,638		
Common collective trust	_		55,678		55,678		
Total fixed							
income	_	2,798	106,316		109,114		
Common stock		27,046	_	_	27,046		
Foreign stock		2,558	_		2,558		
Mutual funds		16,644	_	_	16,644		
Mutual funds international	_	11,204			11,204		
Total equity		57,452			57,452		
Total plan assets	\$	60,250	106,316		166,566		

	June 30, 2015					
	Level 1	Level 2	Level 3	Total		
Managed cash funds Mutual funds – fixed income Common collective trust	3,924	44,207 59,869		3,924 44,207 59,869		
Total fixed income	3,924	104,076		108,000		
Common stock Foreign stock Mutual funds	29,466 2,473 18,135	_	_	29,466 2,473 18,135		
Mutual funds international	11,183			11,183		
Total equity	61,257			61,257		
Total plan assets \$	65,181	104,076		169,257		

There were no significant changes to Level 1 and Level 2 securities between June 30, 2015 and 2016.

The following is a description of the valuation methodologies used for assets measured at fair value:

Corporate bonds: Valued at unadjusted quoted market share prices within active markets or based on external price data of comparable securities.

Common and foreign stock: Valued at unadjusted quoted market share prices within active markets.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

Mutual funds: Valued at the net asset value (NAV) of shares held by the Plans at year-end. Shares traded in an active market.

Common/collective trust funds: Valued at fair value based on the unit value of the fund. Unit values are determined by the bank sponsoring such funds dividing the fund's net assets at fair value by its units outstanding at the valuation date. The Company is required to provide a 90-day notice in order to redeem any amount of investment. There are no other restrictions or gates related to this fund.

iv) Pension Investment Policies

The primary objective of the Medical Center's pension investment program is the long-term growth of capital consistent with the protection of principal during major market declines. The program utilizes several balanced managers and provides for asset allocation guidelines consistent with the Medical Center's risk exposure. The equity portion of the DB Union portfolio may range from 45% to 65% of total portfolio assets with a target of 55% measured at market value. The fixed-income and cash equivalents portion of the DB Union portfolio may range from 35% to 55% of total portfolio assets with a target of 45% measured at market value. The investment program related to the DB Non Union portfolio, which was frozen effective June 30, 2007, has the added objective to protect the principal in preparation for future termination of the plan. A major strategy of the investment program for the DB Non Union portfolio is a de-risking strategy that periodically transfers investments from equity to fixed-income securities based upon pre-established goals and criteria, which are managed by the Company's investment consultants. The distribution of the DB Non Union portfolio as of June 30, 2016 was 31% equities, fixed income 67%, and cash 2%.

The equity segment of the portfolio may include common and preferred stock, convertible securities, warrants, and cash equivalent securities. Equity holdings in any one industry should not exceed 20% of the equity portfolio, holdings in any one economic sector should not exceed 50% of the equity portfolio, and holdings in any one company should not exceed 15% of the equity portfolio. Cash equivalent positions should not exceed 10% of the equity managers' portfolio and no more than 15% of the total portfolio measured at market value shall be invested in small companies, defined as companies of less than \$500 million in market capitalization.

The fixed-income segment of the portfolio may include marketable bonds, preferred stocks, up to 20% in Securities and Exchange Commission (SEC) registered 144 A and securities and cash equivalent securities. With the exception of securities issued by or guaranteed by the U.S. Treasury or U.S. government agencies and instrumentalities, the maximum position in a single issuer's securities should not exceed 5% of the portfolio at market value. The manager is expected to maintain a weighted average bond portfolio quality rating of at least "A." Exposure to below investment grade securities, that is less than "BBB," is limited to a maximum of 20% of the portfolio at market value.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

v) Contributions

The Company expects to contribute \$0 to its DB Union and DB Non Union pension plans in the fiscal year ending June 30, 2017.

(b) Defined Contribution Plan

Effective July 1, 2007, the Company established the GBMC, Inc. 401(a) Defined Contribution Plan (DC Non Union) covering all employees except those covered by the collective bargaining agreement, or employees in a zero hour or registry position. The Company contributes up to 6% of all eligible employee wages (basic contribution) to the plan and the Company matches up to 3% of employee wages of those who contribute to the Greater Baltimore Medical Center, Inc. Voluntary 403(b) Plan. At the discretion of the Board of Directors, the Company may contribute additional funds to the plan.

Expenses for the defined contribution plan for June 30 were as follows:

	 2016	2015
Basic contribution Match contribution	\$ 4,295 3,791	4,179 3,492
Total contribution	\$ 8,086	7,671

Effective July 1, 2009, the Company established the GBMC, Inc. 401(a) Defined Contribution Plan for Members of the Bargaining Union of Greater Baltimore Medical Center (DC Union) for the members covered by a collective bargaining agreement. The Company matches up to 3% of eligible employee wages of those who contribute to the Greater Baltimore Medical Center, Inc. Voluntary 403(b) Plan. The Company contributed \$84 and \$78 for the years ended June 30, 2016 and 2015, respectively.

(c) Nonqualified Plan

The Company has a noncontributory, nonqualified deferred compensation plan for certain key employees. Benefits under the Plan are determined based on increasing percentages (depending on years of service) of base pay. The Company recorded expense related to this plan of \$757 and \$750 for the years ended June 30, 2016 and 2015, respectively.

(11) Asserted and Unasserted Insurance Claims and Contingencies

The Company maintains an offshore captive insurance company in Bermuda to provide coverage for medical malpractice claims. Reserve balances have been discounted at the rate of 3% for the years ended June 30, 2016 and 2015. The receivable for the expected reinsurance recoverable is recorded within other assets on the consolidated balance sheets. Retention on limits in which Ruxton assumes risk of loss is based on an annual occurrence basis of \$3 million per occurrence and \$18 million in aggregate. Amounts in excess of these limits are insured by highly rated commercial insurance companies.

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

As of June 30, 2016 and 2015, the Company was partially self-insured for workers' compensation and health insurance claims. The aggregate reserves for workers' compensation claims were determined and discounted at the rate of 2.7% and 2.6% for 2016 and 2015, respectively. The receivable for the expected reinsurance recoverable is recorded within other current assets on the balance sheet. The Company's excess workers' compensation policy is based on a per claim basis in excess of \$350 plus a corridor deductible of \$750.

The Company is subject to legal proceedings and claims, which arise from the ordinary course of business. In the opinion of management, the amount of ultimate liability with respect to the actions will not materially affect the consolidated financial position of the Company.

The Company recorded reserve activity for claims and claims expense as follows:

		2010		
_	Malpractice	Workers' compensation	Health	Total
\$	31,309	5,728	2,485	39,522
_	14,877	1,106		15,983
	46,186	6,834	2,485	55,505
_	6,837	3,378	2,485	12,700
\$_	39,349	3,456	<u> </u>	42,805
-			5	
	Malpractice	compensation	Health	Total
\$	29,106	5,338	2,548	36,992
_	12,634	2,255		14,889
	41,740	7,593	2,548	51,881
_	6,346	4,749	1,903	12,998
\$_	35,394	2,844	645	38,883
	\$=-	\$ 31,309 14,877 46,186 6,837 \$ 39,349 Malpractice \$ 29,106 12,634 41,740 6,346	Malpractice Workers' compensation \$ 31,309 5,728 14,877 1,106 46,186 6,834 6,837 3,378 \$ 39,349 3,456 Workers' compensation \$ 29,106 5,338 12,634 2,255 41,740 7,593 6,346 4,749	Malpractice compensation Health \$ 31,309 5,728 2,485 14,877 1,106 — 46,186 6,834 2,485 6,837 3,378 2,485 \$ 39,349 3,456 — Workers' Workers' Health \$ 29,106 5,338 2,548 12,634 2,255 — 41,740 7,593 2,548 6,346 4,749 1,903

2016

Notes to Consolidated Financial Statements

June 30, 2016 and 2015

(In thousands)

(12) Promises to Contribute

The Company has received unconditional and conditional promises to give. The pledge receivables are recorded on a discounted basis using the rate in effect at the time of the pledge. Such rates approximate 4%. The Company is the beneficiary of four charitable remainder trusts whose present value as of June 30, 2016 and 2015 was \$1,261 and \$1,258, respectively.

	 2016	2015
Due within 1 year	\$ 5,182	5,124
Due 1–5 years	8,619	4,575
Due over 5 years	 1,261	1,258
Gross pledge receivables	15,062	10,957
Less discount and allowances	 (1,179)	(869)
Net pledge receivables	\$ 13,883	10,088

(13) Controlling and Noncontrolling Interest

The following tables present a reconciliation of the changes in consolidated unrestricted net assets attributable to the Company's controlling interest and noncontrolling interest:

	_	Unrestricted net assets – controlling interest	Unrestricted net assets – noncontrolling interest	Total unrestricted net assets
Balance as of June 30, 2014	\$	387,614	5,331	392,945
Excess of revenues over expenses Pension-related changes other than net		11,598	1,193	12,791
periodic pension costs		(16,149)	_	(16,149)
Distributions to noncontrolling interest owners		_	(1,691)	(1,691)
Net assets released for purchase of fixed assets	_	736		736
Decrease in net assets	-	(3,815)	(498)	(4,313)
Balance as of June 30, 2015	_	383,799	4,833	388,632
(Deficit) excess of revenues over expenses		(2,727)	1,783	(944)
Pension-related changes other than net periodic pension costs Distributions to noncontrolling interest owners Net assets released for purchase of fixed assets		(20,458) — 917	(975) —	(20,458) (975) 917
(Decrease) increase in net assets	_	(22,268)	808	(21,460)
Balance as of June 30, 2016	\$	361,531	5,641	367,172

Notes to Consolidated Financial Statements

June 30, 2016 and 2015


(In thousands)

The noncontrolling interest comprises:

• 50% interest in Greater Baltimore Diagnostic Imaging Partnership that provides medical imaging services on the campus of the Company.

(14) Subsequent Events

The Company has evaluated all events and transactions from the consolidated balance sheet date through October 6, 2016, the date the consolidated financial statements were issued, and determined there are no other items to be recognized or disclosed this period.



Consolidating Balance Sheet

June 30, 2016

(In thousands)

Assets	(Obligated Group) Greater Baltimore Medical Center, Inc.	Ruxton Insurance	GBMC Investments Inc. and Subsidiaries	Gilchrist Hospice Care Inc.	GBHA Inc.	GBMC Land Inc.	GBMC Healthcare Inc. (Parent)	Eliminating entries	Total
Current assets:									
Cash and cash equivalents	\$ 31,448	824	3,616	10,625	14	90	15	_	46,632
Short-term investments and limited or restricted use funds	5,787	3,948	_	2,460	_	_	_	_	12,195
Patient accounts receivable, net Other receivables	46,828 6,759	1,657	1,669 2,215	5,932 1,787	_	560	_	(1,001)	54,429 11,977
Advances to affiliates	19,844	1,057	(57)	1,/8/	_	360	_	(1,001)	11,977
Other current assets	11,171	231	42	114	_		_	(19,787)	11,560
Total current assets	121,837	6.660	7.485	20,918	14	652	15	(20,788)	136,793
Investments and limited use funds	,	.,	.,		14	032	15		,
Interest in net assets of affiliate	219,306	56,794	5,042	79,744	_	_	435,130	(435,130)	360,886
Long-term receivables from affiliates	45,040	_	_	_	_	_	455,150	(45,040)	_
Property and equipment, net	246,952	_	18,523	12,691	92	1,346	_	_	279,604
Other noncurrent assets	9,266	14,877	8,397	2,368		138		(634)	34,412
Total assets	\$ 642,401	78,331	39,447	115,721	106	2,136	435,145	(501,592)	811,695
Liabilities and Net Assets									
Current liabilities:									
Accounts payable and accrued expenses	\$ 60,030	239	437	5,174	_	40	39	(1,001)	64,958
Insurance reserves current	12,550	7,458	_	150	_	_	_	(7,458)	12,700
Payable to affiliates		1,958	10,231	762	_	_	_	(12,951)	
Advances from third-party payors	12,563	_	_	_	_	_	_		12,563
Current portion of long-term debt and capital lease liability	12,102	_	198	_	_	_	_	_	12,300
Other current liabilities	6,462		16	478					6,956
Total current liabilities	103,707	9,655	10,882	6,564	_	40	39	(21,410)	109,477
Long-term debt	130,530	_	_	_	_	_	_	_	130,530
Capital lease liabilities	27,074	_	258	_	_	_	_	_	27,332
Insurance reserves	42,531	39,349	_	274	_	_	_	(39,349)	42,805
Long-term payable to affiliate		_	136	_	5,030	(97)	_	(5,069)	_
Pension liability	60,498	_			_	_	_	_	60,498
Other long-term liabilities	3,872		1,460	615					5,947
Total liabilities	368,212	49,004	12,736	7,453	5,030	(57)	39	(65,828)	376,589
Net assets:									
Unrestricted – controlling	228,858	29,327	21,070	85,665	(4,924)	2,193	361,531	(362,189)	361,531
Unrestricted – noncontrolling			5,641				5,641	(5,641)	5,641
Total unrestricted	228,858	29,327	26,711	85,665	(4,924)	2,193	367,172	(367,830)	367,172
Temporarily restricted	29,394	_	_	8,392	_	_	37,786	(37,786)	37,786
Permanently restricted	15,937			14,211			30,148	(30,148)	30,148
	274,189	29,327	26,711	108,268	(4,924)	2,193	435,106	(435,764)	435,106
Total liabilities and net assets	\$ 642,401	78,331	39,447	115,721	106	2,136	435,145	(501,592)	811,695

See accompanying independent auditors' report.

Consolidating Statement of Operations

June 30, 2016 (In thousands)

	_	(Obligated Group) Greater Baltimore Medical Center, Inc.	Ruxton Insurance	GBMC Investments Inc. and Subsidiaries	Gilchrist Hospice Care Inc.	GBHA Inc.	GBMC Land Inc.	GBMC Healthcare Inc. (Parent)	Eliminating entries	Total
Operating revenues: Patient service revenue net of contractual allowances Provision for uncollectible accounts	\$	412,578 (11,400)		55,404 (543)	48,380 (1,656)					516,362 (13,599)
Net patient service revenue		401,178	_	54,861	46,724	_	_	_	_	502,763
Other operating revenue Net assets released from restrictions	_	12,814 6,664	12,173	9,249	157 3,547		3,190		(19,460)	18,201 10,211
Total operating revenue	_	420,656	12,173	64,110	50,428		3,190	78	(19,460)	531,175
Operating expenses: Salaries, wages and employee benefits Expendable supplies Purchased services Depreciation and amortization Interest Overhead Total operating expenses	_	236,322 81,289 54,871 26,001 7,092 (3,529) 402,046	13,482 — 250 — 13,732	50,246 4,115 17,590 2,852 31 2,319	33,022 3,889 8,538 1,358 31 400 47,238	937 4 205 265 — — 1,411	345 38 3,008 262 — 50	77 37 — 260 374	(1,230) — (18,198) — (7) 	319,719 89,335 79,533 30,738 7,147 — 526,472
Operating income (loss)		18,610	(1,559)	(13,043)	3,190	(1,411)	(513)	(296)	(275)	4,703
Other income: Contributions Fund-raising expense Investment (loss) income, net Interests in net assets of affiliate	_	599 (3,193) (2,354)		(454)	685 (968) (451)		_ 	50 — — (21,434)	(50) 250 (7) 21,434	1,284 (3,911) (3,020)
Excess (deficit) of revenues over expenses	\$_	13,662	(1,313)	(13,497)	2,456	(1,411)	(513)	(21,680)	21,352	(944)

See accompanying independent auditors' report.

Consolidating Statement of Changes in Net Assets

June 30, 2016 (In thousands)

G Ba M	Group) Greater altimore Medical	Ruxton Insurance	GBMC Investments Inc. and Subsidiaries	Gilchrist Hospice Care Inc.	GBHA Inc.	GBMC Land Inc.	GBMC Healthcare Inc. (Parent)	Eliminating entries	Total
\$	13,662	(1,313)	(13,497)	2,456	(1,411)	(513)	(21,680)	21,352	(944)
	(20,458) 917 — 674		(975) (1,677)			 786	 	 	(20,458) 917 (975)
	(5,205)	(1,313)	(16,149)	2,456	(1,411)	273	(21,463)	21,352	(21,460)
	8,452 (581) — (917) (6,664)	 		5,279 (414) — — (3,547)		_ _ _ _ 	1,608	(2) (1,608) —	13,731 (997) — (917) (10,211)
	290			1,318			1,608	(1,610)	1,606
	1,555 — —			140 			 1,586 	(1,586)	1,697 — (111)
	1,555			29			1,586	(1,584)	1,586
	(3,360)	(1,313)	(16,149)	3,803	(1,411)	273	(18,269)	18,158	(18,268)
	277,549	30,640	42,860	104,465	(3,513)	1,920	453,375	(453,922)	453,374
\$	274,189	29,327	26,711	108,268	(4,924)	2,193	435,106	(435,764)	435,106
	Ba M Ce	(20,458) 917 — 674 (5,205) 8,452 (581) — (917) (6,664) 290 1,555 — 1,555 (3,360) 277,549	Group) Greater Baltimore Medical Center, Inc. \$ 13,662 (1,313) (20,458) — 917 — 674 — (5,205) (1,313) 8,452 — (581) — (917) — (6,664) — 290 — 1,555 — 1,555 — 1,555 — 1,555 — (3,360) (1,313) 277,549 30,640	Group) Greater Baltimore Ruxton Investments Inc. and Subsidiaries \$ 13,662 (1,313) (13,497) (13,497) \$ 13,662 (1,313) (13,497) (13,497) \$ 13,662 (1,313) (13,497) (1,677) \$ 13,662 (1,313) (16,149) (1,677) \$ 1,5205 (1,313) (16,149) (16,149) \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - \$ 1,555 - - - <td< td=""><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Investments Inc. and Subsidiaries Gilchrist Hospice Care Inc. \$ 13,662 (1,313) (13,497) 2,456 (20,458) 917 — — — — — — — — — — — 674 — (1,677) — (5,205) (1,313) (16,149) 2,456 8,452 (581) — — 5,279 (414) — — — — (917) — — — — — — — (6,664) — — — — — — 1,318 1,555 — — — — — — — — — — — — — — — (6,664) — — — — — — — <tr< td=""><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance Inc. and Subsidiaries Gilchrist Hospice Care Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (20,458) — — — — 917 — — — — 674 — (1,677) — — (5,205) (1,313) (16,149) 2,456 (1,411) 8,452 — — 5,279 — (581) — — — — (917) — — — — (917) — — — — (6,664) — — 1,318 — 1,555 — — 140 — — — — — — — — — — — 1,555 — — — — — — — — — <</td><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Inc. and Subsidiaries Gilchrist Hospice Care Inc. GBHA Inc. Land Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (20,458) — — — — — 917 — — — — — 674 — (1,677) — — — 674 — (1,677) — — — (5,205) (1,313) (16,149) 2,456 (1,411) 273 8,452 — — — — — — (581) — — 4(14) — — (917) — — — — — (917) — — — — — (917) — — — — — (6,664) — — — — — — —</td><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance Investments Inc. and Subsidiaries Gilchrist Hospice Care Inc. GBHA Inc. GBMC Healthcare Inc. Healthcare Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (21,680) (20,458) — — — — — — — 917 — — — — — — — 674 — (975) — — — — — 674 — (1,677) — — 786 217 (5,205) (1,313) (16,149) 2,456 (1,411) 273 (21,463) 8,452 — — — — — — — (581) — — — — — — — (917) — — — — — — — (6,664) — — — — —</td><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Investments Inc. and Subsidiaries GBHA Inc. GBMC Inc. Healthcare Inc. Eliminating entries \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (21,680) 21,352 (20,458) — — — — — — — — 917 —</td></tr<></td></td<>	Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Investments Inc. and Subsidiaries Gilchrist Hospice Care Inc. \$ 13,662 (1,313) (13,497) 2,456 (20,458) 917 — — — — — — — — — — — 674 — (1,677) — (5,205) (1,313) (16,149) 2,456 8,452 (581) — — 5,279 (414) — — — — (917) — — — — — — — (6,664) — — — — — — 1,318 1,555 — — — — — — — — — — — — — — — (6,664) — — — — — — — <tr< td=""><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance Inc. and Subsidiaries Gilchrist Hospice Care Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (20,458) — — — — 917 — — — — 674 — (1,677) — — (5,205) (1,313) (16,149) 2,456 (1,411) 8,452 — — 5,279 — (581) — — — — (917) — — — — (917) — — — — (6,664) — — 1,318 — 1,555 — — 140 — — — — — — — — — — — 1,555 — — — — — — — — — <</td><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Inc. and Subsidiaries Gilchrist Hospice Care Inc. GBHA Inc. Land Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (20,458) — — — — — 917 — — — — — 674 — (1,677) — — — 674 — (1,677) — — — (5,205) (1,313) (16,149) 2,456 (1,411) 273 8,452 — — — — — — (581) — — 4(14) — — (917) — — — — — (917) — — — — — (917) — — — — — (6,664) — — — — — — —</td><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance Investments Inc. and Subsidiaries Gilchrist Hospice Care Inc. GBHA Inc. GBMC Healthcare Inc. Healthcare Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (21,680) (20,458) — — — — — — — 917 — — — — — — — 674 — (975) — — — — — 674 — (1,677) — — 786 217 (5,205) (1,313) (16,149) 2,456 (1,411) 273 (21,463) 8,452 — — — — — — — (581) — — — — — — — (917) — — — — — — — (6,664) — — — — —</td><td>Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Investments Inc. and Subsidiaries GBHA Inc. GBMC Inc. Healthcare Inc. Eliminating entries \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (21,680) 21,352 (20,458) — — — — — — — — 917 —</td></tr<>	Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance Inc. and Subsidiaries Gilchrist Hospice Care Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (20,458) — — — — 917 — — — — 674 — (1,677) — — (5,205) (1,313) (16,149) 2,456 (1,411) 8,452 — — 5,279 — (581) — — — — (917) — — — — (917) — — — — (6,664) — — 1,318 — 1,555 — — 140 — — — — — — — — — — — 1,555 — — — — — — — — — <	Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Inc. and Subsidiaries Gilchrist Hospice Care Inc. GBHA Inc. Land Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (20,458) — — — — — 917 — — — — — 674 — (1,677) — — — 674 — (1,677) — — — (5,205) (1,313) (16,149) 2,456 (1,411) 273 8,452 — — — — — — (581) — — 4(14) — — (917) — — — — — (917) — — — — — (917) — — — — — (6,664) — — — — — — —	Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance Investments Inc. and Subsidiaries Gilchrist Hospice Care Inc. GBHA Inc. GBMC Healthcare Inc. Healthcare Inc. \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (21,680) (20,458) — — — — — — — 917 — — — — — — — 674 — (975) — — — — — 674 — (1,677) — — 786 217 (5,205) (1,313) (16,149) 2,456 (1,411) 273 (21,463) 8,452 — — — — — — — (581) — — — — — — — (917) — — — — — — — (6,664) — — — — —	Group) Greater Baltimore Medical Center, Inc. Ruxton Insurance GBMC Investments Inc. and Subsidiaries GBHA Inc. GBMC Inc. Healthcare Inc. Eliminating entries \$ 13,662 (1,313) (13,497) 2,456 (1,411) (513) (21,680) 21,352 (20,458) — — — — — — — — 917 —

See accompanying independent auditors' report.